83 results about "Cholesterol phosphate" patented technology

PCT No. PCT/US97/06725 Sec. 371 Date Aug. 10, 1998 Sec. 102(e) Date Aug. 10, 1998 PCT Filed Apr. 21, 1997 PCT Pub. No. WO97/44314 PCT Pub. Date Nov. 27, 1997The instant invention is new compounds of Formula I their use as cerebrovascular agents in diseases such as stroke, peripheral vascular disease, restenosis, and as agents for regulating plasma cholesterol concentrations, for treating hypercholesterolemia and atherosclerosis, and for lowering the serum or plasma level of Lp(a). A pharmaceutical composition is also claimed.

Oral compositions, suitable for chewing, comprising a gel-forming polysaccharide isolated from psyllium seed husks and an excipient that is fast dissolving in the oral cavity, provide good aesthetics and acceptable mouthfeel as perceived by the consumer. The oral compositions are useful for normalizing bowel function, reducing human serum cholesterol levels and treatment of other gastrointestinal disorders.

Methods of treating high serum levels of total cholesterol, low density lipoprotein and triglycerides in a mammal by administering therapeutically effective doses of N-(4-{[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]amino}phenyl)acetamide or a salt thereof such as a hydrochloride or hydrobromide salt.

The invention discloses a method for preparing proanthocyanidins liposomes, and relates to a method for preparing liposomes. The method solves the problems of large grain size and difficult absorption of a human body by protecting proanthocyanidins in a microcapsule form in the prior art. The method comprises the following steps of: 1, putting soya bean lecithin and cholesterol in a pear-shape flask, adding mixed solution of diethyl ether and absolute ethyl alcohol, adding proanthocyanidins and phosphate buffer, and mixing to obtain mixed solution; 2, performing ultrasonic processing on the mixed solution in a 25 DEG C water bath, performing rotary evaporation to form a film in a water bath at the temperature of between 30 and 50 DEG C and under the pressure of between 400 and 700MPa, adding phosphate buffer again, and performing hydration to obtain coarse suspension; and 3, and filtering the coarse suspension by using a filter membrane of 0.45 mu m. The liposomes are adopted for encapsulating the proanthocyanidins, so the proanthocyanidins are more stable, have small grain size and target, and are favorable for absorption of the human body; the encapsulation rate of the proanthocyanidins liposomes is 88.89 percent; and the preparation process is simple.

The invention relates to an oral drug composite for reducing the blood fat, in particular to a drug composite which takes any 1-2 of statins zinc salt and nicotinic acidniacin blood fat reducing medicine or fibrates blood fat reducing medicine or cholesterol restraining and absorbing medicine as active ingredients, the preparation of the drug composite, and the use of the drug composite. The drug composite takes the statins zinc salt and the nicotinic acidniacin blood fat reducing medicine or the fibrates blood fat reducing medicine or the cholesterol restraining and absorbing medicine as the active ingredients and takes the corresponding ingredients as the drug auxiliary materials. The oral preparation which is prepared according to the technology and the method of the patent description comprises granular formulation, conventional tablet, chewable tablet, dispersible tablet, orally disintegrating tablet, buccal tablet, capsule, soft capsule, pill, sustained release tablet, sustained release capsule and the like. The oral drug composite is quick and durable in effect, and is convenient to take, thereby being used for treating various hyperlipemias.

Belonging to the field of medical technologies, the present invention discloses application of aloe-emodin in preparation of drugs reducing blood lipid and liver lipid. Specifically, blood lipid refers to total cholesterol and low density lipoprotein in serum, and liver lipid refers to total cholesterol in liver. Toxicity tests show that aloe-emodin has no obvious toxic and side effect. Pharmacodynamic tests of aloe-emodin show that aloe-emodin can significantly reduce the total cholesterol and low density lipoprotein in hyperlipidemia animal model serum, and has obvious blood lipid reducing effect. At the same time, aloe-emodin can also significantly reduce the total cholesterol content of a hyperlipidemia animal model liver, and has obvious liver lipid reducing effect. Therefore, the invention puts forward the application of aloe-emodin in reduction of blood lipid and liver lipid, aloe-emodin has the characteristics of significant lipid reducing effect, low toxicity, no irritation, low price, and convenient production, transportation, storage and taking, and can have broad application prospects as a blood lipid and liver lipid reducing drug.

The present invention relates to the use of a composition comprising a combination of diacylglycerol(s) (DAG), mainly 1,3-diacylglycerol(s), and phytosterol and/or phytostanol ester(s) (PSE) dissolved or dispersed in edible oil and/or edible fat, in the manufacture of nutritional supplements and orally administrable pharmaceutical preparations which are capable of reducing blood levels of both cholesterol and triglycerides and/or for lowering serum, serum LDL and macrophage oxidation levels, inhibiting the formation of foam cells and/or preventing the deleterious effects generated by lipid-induced oxidative stress. In addition, the composition of the invention, as well as the pharmaceutical preparations thereof, is suitable for the treatment and prevention of conditions related to atherosclerosis, such as cardiovascular disease (CVD), coronary heart disease (CHD) and diabetes mellitus.

The present invention relates to novel sulfoxide and bis-sulfoxide compounds, compositions comprising sulfoxide and bis-sulfoxide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

A nutritional composition comprising phospholipids, sphingolipids and cholesterol for the prevention of obesity and/or diabetes is provided.

The invention relates to the use of piperic acid ester compound in preparation of drug or healthcare product for reducing blood fat, wherein R1, R2, R3 are defined in the description, the piperic acid ester compounds represented by formula (1) have the actions of substantially reducing cholesterin, triglyceride and increasing high density lipoprotein, fully activating lecithin cholesterol acyl transferase, forwarding extra-hepatic tissue cholesterol to liver, cleaning out plasma lipoproteins, plasma cholesterol and cholesterol esters, thus can be applied to the prevention and treatment of cardiovascular and cerebrovascular diseases, cerebrovascular, coronary artery and peribiliary vessel pathology and hyperlipemia.

A method and a composition for making a composition, tablet, or tablet core having cross-linked polyallylamine salts such as sevelamer hydrochloride, sevelamer carbonate, or colesevelam hydrochloride, that may be used for treating hyperphosphatemia or reducing cholesterol. The method involves blending of a cross-linked polyallylamine salt with a water soluble excipient, optionally with water, an additive and/or a lubricant, and further tableting the resulting blend to form tablets and tablet cores.

The invention provides the cation lipid containing imidazolium salt and macrocyclic polyamines. The cation lipid has a structural formula below. In the formula, R is cholesteryl or saponin group. The transgenetic vector is prepared from the cation lipid containing imidazolium salt and macrocyclic polyamines, the cholesterol and deionized water; and in the transgenetic vector, the molar concentration of the cation lipid containing imidazolium salt and macrocyclic polyamines is 1 to 4mmol/L/, and the molar ratio of the cation lipid containing imidazolium salt and macrocyclic polyamines to the cholesterol is 1-2:1.

The invention discloses a cholesterol hybrid compound of molybdenum-containing polyoxometallate, comprising a chemical formula of [(n-Bu)4N]3{MnMo6O18[(OCH2)3CNHCOC30H49O2]2}. The invention further discloses a preparation method of the cholesterol hybrid compound, which comprises the following steps of: with cholesterol as starting materials, reacting the cholesterol with succinic anhydride to obtain cholesteryl hemisuccinate; and reacting the molybdenum-containing polyoxometallate with an Anderson structure with the cholesteryl hemisuccinate to obtain hybrid compounds which are bonded by covalent bonds. The invention has the advantages that: by adopting an organic-inorganic hybridization method, chemical modification is carried out on the molybdenum-containing polyoxometallate, so that the molybdenum-containing polyoxometallate is bonded with the cholesterol by covalent bonds for the first time; moreover; the preparation method provided by the invention has the advantages of convenience and feasibility in operation, simpleness in purification, higher productivity and convenience for popularization and application; and the hybrid compound provided by the invention has potential application values on medicine, biology, catalyst, surfactant and the like.

The invention relates to a precursor liposome of propolis flavone and a preparation method thereof. The method is characterized by comprising the following steps of: preparing a nanometer liposome suspension of the propolis flavone by a reverse-phase evaporation method, and freeze drying the nanometer liposome suspension of the propolis flavone to prepare the precursor liposome of the propolis flavone; and preparing a nanometer liposome of the propolis flavone with Tween 80 by taking the propolis flavone as cores and lecithin and cholesterol as membranes, and freeze drying the prepared nanometer liposome of the propolis flavone by the reverse-phase evaporation method to obtain the precursor liposome of the propolis flavone. Due to the adoption of the technical scheme, the stability of the propolis flavone in a strongly-acidic system of gastric acid can be enhanced to improve biological availability and achieve better health-care effect. The precursor liposome of the propolis flavone prepared by the freeze drying method can be convenient to store and convey and also can be applied in wide food systems.

The present invention provides a simple and sensitive aqueous method for determining cholesterol in remnant-like particles in a biological sample without the separation of components of the sample. The method comprises contacting the sample with (i) cholesterol esterase, (ii) cholesterol oxidase or cholesterol dehydrogenase, and (iii) phospholipase with a surfactant that inhibits cholesterol oxidase or cholesterol dehydrogenase in lipoproteins other than remnant-like particles in the presence of oxygen or an oxidized coenzyme. Formed hydrogen peroxide or reduced coenzyme is measured and correlated to a quantitative determination of cholesterol in remnant-like particles.

The invention discloses an oxaliplatin liposome and an application thereof. Preparation raw materials of the oxaliplatin liposome comprise oxaliplatin, phospholipid, cholesterol and poloxamer F68; the mass ratio of phospholipid to cholesterol is (3 to 8):1; the mass ratio of oxaliplatin to phospholipid is 1:(30 to 60); and the mass ratio of poloxamer F68 to phospholipid is 1:(5 to 15). The oxaliplatin liposome obtained by the invention has a small particle size and high entrapment efficiency, adopts the cheap raw materials and a simpler process and is suitable for industrial mass production.

Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

The invention belongs to the technical field of preparation of phospholipid membranes and discloses a preparation method of a bionic phospholipid membrane with a controllable shape. The preparation method comprises the following steps: after mixing phospholipid and cholesterol, dissolving with an organic solvent; carrying out rotary evaporation to remove the organic solvent to obtain a phospholipid thin film; carrying out hydration and homogenization treatment on the obtained phospholipid thin membrane in sequence to obtain a vesicle solution with the grain diameter range of 50 to 150nm; afterdiluting the obtained vesicle solution by utilizing a hydration solution, enabling the vesicle solution to flow through the surface of a gold sheet, so as to enable phospholipid vesicles to be adsorbed on the surface of the gold sheet to reach saturation; then washing a vesicles adsorption layer on the surface of the gold sheet by utilizing the hydration solution, so as to obtain the bionic phospholipid membrane, wherein the hydration solution is a Tris buffering solution or a water solution which contains or does not contain metal cations. The phospholipid membranes with different shapes areprepared on the same surface through controlling types of the metal cations in the solution, and resources are saved; a preparation process has good stability and repeatability; an operation processis simple and the prepared bionic phospholipid membrane has a few of defects.

The invention relates to a method of extracting bilirubin from bile and simultaneously co-producing cholesterol and lecithin. The method comprises the following steps: breaking a gallbladder to obtain bile, filtering bile to remove impurities; subjecting the bile to an alkalization treatment and a centrifugal treatment in sequence, collecting the filtrate, directly subjecting the filtrate to spray-drying to obtain dry powder, adding dry powder into a mixed solvent, carrying out extraction under a subcritical condition to obtain fat containing extract and degreased powder; adding fat containing extract into acetone, carrying out reflux extraction, collecting the filtrate and filter residues; evaporating and concentrating the filtrate, extracting cholesterol from concentrated filtrate, recovering the filter residues, extracting lecithin from filter residues; adding water and dichloromethane into degreased powder to form an extraction liquid, carrying out extraction to obtain suspension in the upper layer and a red liquid in the lower layer; extracting bilirubin from the red liquid, and extracting cholic acid from the suspension. The provided method can extract bilirubin, cholic acid, cholesterol and lecithin from bile at the same time, bile is comprehensively utilized, resources are saved, energy consumption is reduced, and sustainable development is realized.

The invented immobilization technology of beta-cyclodextrin (including chemical grafting process and physical blending process) not only can fix beta-cyclodextrin to the chitosan carrier to adsorb the cholesterine and triglyceride being in the food or blood plasma, but also can utilzie desorption technology to desorb the triglyceride and cholesterine from beta-cyclodextrin on the chitosan carrier. The desorbed triglyceride and cholesterine can be recovered, and can be used for develop by-product, for example, can be used as feed, and the chitosan carrier also can be reused by make adsorption.